National Diabetes Audit - Report 1 Care Processes and Treatment Targets 2017-18, Full Report
This is part of National Diabetes Audit
- Publication date:
- 13 Jun 2019
- Geographic coverage:
- England, Wales
- Geographical granularity:
- Clinical Commissioning Groups, London Authorities, GP practices, Hospital Trusts
- Date range:
- 01 Jan 2017 to 31 Mar 2018
The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK.
The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes.
This report details the findings for the 2017-18 audit. The audit collected data during May and June 2018, for the period 01 January 2017 to 31 March 2018 and contains the full key findings, recommendations and new analysis relating to cardiovascular disease (CVD) risk, including new treatment targets showing statin prescriptions for CVD risk reduction.
This report follows the NDA short report publication in November 2018, which provided the top level findings for the 2017-18 audit, along with local level data made available to services in a timely manner that can help drive improvements in the quality of diabetes care locally.